MMR vaccine safety in kids after heart transplant
Part of Infections, Mouth & dental clinical trials.
This trial tests whether the MMR (measles, mumps, rubella) vaccine is safe and works well for children who have had a heart transplant. It may help protect you from these diseases if you haven't had the vaccine or no longer have immunity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have received a heart transplant
- It has been at least 1 year since your transplant
- It has been at least 1 year since you had treatment for antibody-mediated rejection
- It has been at least 6 months since you had high-dose steroids or basiliximab
- You have never had the MMR vaccine, or you had it but now lack protection against measles
- You are generally feeling well and healthy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This trial tests two RSV vaccine schedules in people who have had a lung transplant or a stem cell transplant. It looks at whether the vaccines are safe and how well they boost the immune system against RSV, a common respiratory virus.
This study tests a new approach to managing anti-rejection medicines after a heart transplant. It uses special blood tests to see if your immune system is calm, so doctors can safely reduce the medicines and lower side effects.
This study tests a drug called belatacept, which may help prevent the body from rejecting a new heart. It is given after a heart transplant, and the goal is to see if it works as well as or better than standard anti-rejection medicines.
This trial tests whether Thymoglobulin® is safe and how well it works in people getting their first heart transplant. It may help doctors fine-tune medicines used to prevent the body from rejecting the new heart.
This trial studies whether belatacept, an anti-rejection medicine given by IV, can work for people receiving their first heart transplant. It aims to see if it prevents rejection safely for patients and whether it fits better than standard approaches for certain candidates.
Hear when a new Heart Transplant Infection Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.